# A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)

Study · id `cardio:ct-nct01194154` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01194154](<https://clinicaltrials.gov/study/NCT01194154>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01194154

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

## Technical summary

Registry record NCT01194154. Randomized; single masking; primary purpose treatment. Start 2010-09-30 (actual); primary completion 2015-03-31 (actual). Results posted on 2016-06-14.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 241 participants (enrolled count; ClinicalTrials.gov record NCT01194154, source copy `cardio:ctgov-nct01194154-2017-05-10`, retrieved 2026-10-26)
- Started: 2010-09-30 (actual) (ClinicalTrials.gov record NCT01194154, source copy `cardio:ctgov-nct01194154-2017-05-10`, retrieved 2026-10-26)
- Primary completion: 2015-03-31 (actual) (ClinicalTrials.gov record NCT01194154, source copy `cardio:ctgov-nct01194154-2017-05-10`, retrieved 2026-10-26)
- Completion: 2015-03-31 (actual) (ClinicalTrials.gov record NCT01194154, source copy `cardio:ctgov-nct01194154-2017-05-10`, retrieved 2026-10-26)
- Results first posted: 2016-06-14 (ClinicalTrials.gov record NCT01194154, source copy `cardio:ctgov-nct01194154-2017-05-10`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT01194154, source copy `cardio:ctgov-nct01194154-2017-05-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01194154-2017-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
- Condition: Kidney Disease, Chronic
- Intervention (Drug): Methoxy polyethylene glycol-epoetin beta
- Intervention (Drug): Placebo
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: 915dd314675402675e6f6e55594dd7f2b7e093957e4cd7022b36522967b7e959
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
